ClinicalTrials.gg
CompletedNCT03257631Updated Apr 16, 2024Results posted

A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors

A Phase 2 interventional study of Pomalidomide and Pomalidomide in Central Nervous System Neoplasms and Medulloblastoma, sponsored by Celgene. Completed at 22 sites in 5 countries. Open to participants aged 1 Year to 21 Years. Per ClinicalTrials.gov, last updated 2024-04-16.

Primary conditionBrain NeoplasmsRegistry: Central Nervous System NeoplasmsReclassifiedWhy we changed it
Registry
Central Nervous System Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Brain Neoplasms
Why
  1. The study's title name Brain Neoplasms, a narrower term within Central Nervous System Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
1 Year to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 172 studies in Brain Neoplasms with a site in France — 38 open to participants now, 53 under way, 6 of them phase 3. Brain Neoplasms · France.

Enrollment
79th of 132
53 · median 70
Started
2017
with 4 others
Phase 2
40 of 172
3 open now
Registered
86th of 172
by date

Among the 172 studies in Brain Neoplasms with a site in France, this one is the 79th largest by enrollment of the 132 interventional ones that give a count, is one of 5 that started in 2017, is one of 40 in phase 2, and was the 86th registered.

Brain Neoplasms

2,441 studies on the registry are indexed under Brain Neoplasms; 541 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

38 of the 172 studies in Brain Neoplasms with a site in France are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 424 Brain Neoplasms studies recruiting now, 285 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 36 take healthy volunteers.

This study: 1 Year to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 172 studies in Brain Neoplasms with a site in France, or all of them as a file.
02

Study summary

This study will assess the efficacy, safety and tolerability of pomalidomide in children and young adults aged 1 to \< 21 years with recurrent or progressive primary brain tumors in one of four primary brain tumor types: high-grade glioma (HGG), medulloblastoma, ependymoma and diffuse intrinsic pontine glioma (DIPG).

Read the detailed description

The study will consist of 4 parallel groups of participants, one for each of the following primary brain tumor types: high-grade glioma, medulloblastoma, ependymoma and DIPG. A Simon's Optimal two-stage study design will be applied to each group and enrollment will occur as follows:

  • Stage 1: Nine participants will be enrolled in each brain tumor type group
  • Stage 2: If during Stage 1, ≥ 2 participants achieves either an objective response (either complete response or partial response) within the first 6 cycles of treatment (or within the first 3 cycles for DIPG participants), or a long-term stable disease, an additional 11 participants shall be enrolled; otherwise no additional participants will be enrolled into that group.
  • If a total of 5 or more participants across all 20 participants in a given group (Stage 1 and 2) evaluable for the primary endpoint are observed as having either an objective response (either complete response or partial response) within the first 6 cycles of treatment (or within the first 3 cycles for DIPG participants) or a long-term stable disease, pomalidomide will be considered effective in that disease indication.

Once treatment has been discontinued, participants will be followed up for up to 5 years from enrollment of the last participant.

Participants who withdraw from either stage for reasons other than disease progression prior to completing Cycle 1 of study treatment will be replaced.

03

Conditions studied

  • Central Nervous System Neoplasms
  • Medulloblastoma

Keywords

  • Pediatric
  • Brain Tumor
  • Central Nervous System Neoplasms
  • Glioma
  • High-grade glioma
  • HGG
  • Ependymoma
  • Medulloblastoma
  • DIPG
  • Diffuse intrinsic pontine gliomaProgressive
  • RecurrentPomalidomide
  • PomalystImnovid
  • CC-4047
  • Children
04

In context

Brain Neoplasms Reclassified

2,441 studies on the registry are indexed under Brain Neoplasms; 541 are open to participants now.

This study's enrollment of 53 is above the median of 40 across 1,832 interventional studies indexed under Brain Neoplasms.

Browse Brain Neoplasms studies →

Lead sponsor

Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.

Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.

First submitted before Celgene became part of Bristol-Myers Squibb.

Compared within Brain Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Central Nervous System Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
1 Year to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is 1 to \< 21 years of age at the time of signing the Form/Informed Assent Form (ICF/IAF).
  2. Subject (when applicable, parental/legal representative) must understand and voluntarily sign an ICF/IAF prior to any study-related assessments/procedures being conducted.
  3. Subject has received at least one prior standard therapy (or generally accepted upfront therapy if no standard exists) and have no known curative therapy.
  4. Subject has a diagnosis of high-grade glioma, medulloblastoma, ependymoma or diffuse intrinsic pontine glioma (DIPG) that is recurrent or progressive. Subjects with neurofibromatosis type 1 (NF-1) associated tumors are eligible if they meet all other eligibility criteria.
  5. Subject has histological verification of tumor either at the time of diagnosis or recurrence. Subjects with DIPG are exempt from histologic verification if they have typical magnetic resonance imaging (MRI) findings of DIPG
  6. Subject has defined as a tumor that is measurable in 2 perpendicular diameters on MRI. For a lesion to be considered measurable, it must be at least twice the slice thickness on MRI (ie, visible on 2 or more axial slices)
  7. To document the degree of tumor at study baseline, the following scan(s) must be obtained:

    • A brain MRI with and without contrast (ie, gadolinium) and a spine MRI with contrast within 21 days prior to first dose of study treatment. For subjects on , baseline MRI scans must be performed while on stable or decreasing dose of steroids for at least 5 days.
  8. Subject has (age ≥ 16 years) or Lansky (age \< 16 years) performance status score ≥ 50 at screening
  9. Subject has adequate bone marrow function defined as:

    • Peripheral (ANC) ≥ 1000/mm³
    • count ≥ 100,000/mm³ (transfusion independent defined as no platelet transfusion within 7 days and recovery from nadir)
    • ≥ 8 g/dL (red blood cell [RBC] transfusion is allowed)
  10. Subject has adequate renal function defined as:

    • Serum creatinine based on age/gender calculated using the Schwartz formula, or a 24-hour or radioisotope (GFR) (radioisotope or iothalamate) ≥ 70 mL/min/1.73 m².
  11. Subject has adequate liver function defined as:

    • Total ≤ 1.5 X (ULN) for current age (≤ 3 X ULN if increase in bilirubin is attributable to Gilbert's Syndrome)
    • (ALT) (SPGT) is ≤ 3 X ULN for age
    • Serum albumin ≥ 3 g/dL
  12. Subject has adequate pulmonary function defined as:

    • No evidence of dyspnea at rest
    • A pulse oximetry ≥ 93%
  13. Subject has recovered from acute treatment related toxicities from all prior therapies. Recovery is defined as a toxicity Grade ≤ 2 ( [CTCAE] v. 4.03).
  14. Subject has no significant worsening in clinical status for a minimum of 7 days prior to first dose of study drug.
  15. Subject (and when applicable, with parental/legal representative) is willing and able to adhere to the study visit schedule and other protocol requirements.
  16. Females of (FCBP) and male subjects who have reached puberty (and when applicable, with parental/legal representative) must agree to undergo physician-approved reproductive education and discuss the side effects of the study therapy on reproduction.
  17. Females of childbearing potential must agree and meet the following conditions below:

    • Medically supervised (ie, performed in a clinic) pregnancy testing, including those who commit to true abstinence. Two pregnancy tests must be conducted prior to starting pomalidomide. The first pregnancy test must be performed 10 to 14 days prior to the start of pomalidomide and the second pregnancy test must be performed within 24 hours prior to starting pomalidomide. Females of childbearing potential with regular or no menstrual cycles must also agree to have pregnancy tests weekly for the first 28 days study participation, every 28 days while on study, at study treatment discontinuation, and at Day 28 following pomalidomide discontinuation. If menstrual cycles are irregular, the pregnancy testing must occur weekly for the first 28 days of study participation and then every 14 days while on study, at study treatment discontinuation visit, and at Days 14 and 28 following pomalidomide discontinuation.
    • Female subjects must, as appropriate to age and at the discretion of the study Investigator, either commit to true abstinence from heterosexual contact and/or agree to the use of two reliable forms of approved and effective methods simultaneously. The two methods of reliable contraception must include one highly effective method (ie, oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; vasectomized partner) and one additional effective barrier method (ie, male condom, diaphragm, cervical cap) 28 days prior to starting pomalidomide, throughout the entire duration of study treatment including dose interruptions and 28 days after discontinuation of pomalidomide.
    • All male and female subjects must follow all requirements defined in the pomalidomide Pregnancy Prevention Program.
  18. Male subjects must, as appropriate to age and the discretion of the study physician:

    • Practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of child bearing potential while participating in the study, during dose interruptions and for at least 28 days following pomalidomide discontinuation, even if he has undergone a successful vasectomy or practices complete abstinence.

Exclusion criteria

Exclusion Criteria:

  1. Subject has a history of non-central line related thrombosis (arterial or venous), more than one prior central-line related thrombosis or known coagulopathy.
  2. Subject has first degree family member with a known hereditary coagulopathy.
  3. Subject is actively on anticoagulation therapy.
  4. Subject has had major (per Investigator discretion) surgery, with the exception of tumor resection, within 21 days from first dose of study drug.
  5. Subject has previously received (presence of any of the following will exclude a subject from enrollment):

    • Any prior treatment with pomalidomide. Subjects who have prior treatment with other immunomodulatory compounds (thalidomide, lenalidomide) are eligible if they meet all other eligibility criteria and did not have allergic reactions or other "significant toxicity" per Investigator discretion associated with lenalidomide or thalidomide use.
    • Myelosuppressive chemotherapy, immunotherapy, or any agent: ≤ 21 days (≤ 42 days if a nitrosourea) prior to screening.
    • Biological (anti-neoplastic) therapy: ≤ 7 days prior to screening.
    • Immunomodulatory therapy: ≤ 28 days prior to screening.
    • Monoclonal antibody treatment and agents with known prolonged half-lives: \< 3 halflives have elapsed or ≤ 28 days prior to screening, whichever is longer.
    • Prior radiation:

      • Cranial irradiation, total body irradiation (TBI), or ≥ 50% radiation of pelvis ≤ 3 months prior to screening.
      • Focal irradiation: ≤ 3 weeks prior to screening if radiation field involved a nontarget lesion; ≤ 6 weeks prior to screening if radiation field involved a target lesion.

    Note: True disease progression following prior irradiation therapy must be confirmed by Investigator prior to screening.

    • Bone marrow transplant:

      • Presence of (GVHD).
      • \< 6 months since bone marrow transplant prior to screening.
      • \< 3 months since autologous bone marrow/stem cell transplant prior to screening.
      • \< 3 months since stem cell transplant (SCT) or Rescue without TBI with no evidence of GVHD prior to screening.
    • Radioisotopes: fluorothymidine (18FLT) ≤ 72 hours prior to first dose of study drug
  6. Subject has received therapy with a known moderate to potent CYP1A2 inhibitor within 14 days or 5 half-lives of first dose of study treatment (whichever is longer).
  7. Subject has received colony-stimulating growth factor(s) within 7 days prior to screening (or within 14 days if subject received polyethylene glycol formulations).
  8. Subject is pregnant, breast-feeding or lactating.
  9. Subject has an untreated or uncontrolled infection defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment.
  10. Subject has active infectious hepatitis, type A, B, or C, or chronic carriers of .
  11. Subject has any prior history of , other than high-grade glioma, medulloblastoma, ependymoma or DIPG (Note: radiation-associated gliomas are excluded from enrollment)
  12. Subject who, in the opinion of the Investigator, has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
  13. Subject has any condition including the presence of laboratory abnormalities which, in the opinion of the Investigator, places the subject at unacceptable risk if he/she were to participate in the study.
  14. Subject has any condition that confounds the ability to interpret data from the study.
  15. Subject has symptomatic cardiac disorders ( v. 4.03 Grade 3 and 4).
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Pomalidomide

    Pomalidomide will administered at a starting dose of 2.6 m2/day. Pomalidomide will be provided as either a capsule (0.5 mg, 1 mg, 2 mg, 3 mg or 4 mg) or as an oral suspension (2 mg/mL).

    Drug: Pomalidomide

Interventions

  • : Subjects will be administered pomalidomide on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle and will continue treatment for up to 24 cycles or until disease progression, withdrawal of consent/assent or unresolved toxicities as described in the protocol.

    Also known as: CC-4047

  • Pomalidomide will be provided as gelatin capsules and as an oral suspension. The starting dose will be 2.6 mg/m²/day, administered on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle.

    Also known as: CC-4047, Pomalyst®

07

What researchers measure

Primary outcomes

  1. Percentage of Participants With an Objective Response and Long-term Stable Disease

    The percentage of participants who achieved either an objective response, defined as a complete response (CR) or partial response (PR) in the first 6 cycles of treatment (or within 3 cycles for DIPG), or long-term stable disease (SD) defined as SD maintained for ≥ 6 cycles (≥ 3 cycles for DIPG), measured from first dose date. CR: Disappearance of all lesions and no new lesions. PR: A reduction of ≥ 50% in the size of measurable lesions, and/or persistence of non-target lesions with no progression or decrease in size. SD: A decrease of \< 50% or an increase of \< 25% in the size of measurable lesions and no evidence of new lesions, response does not meet the criteria for CR, PR, or progressive disease, and/or the persistence of non-target lesions with no progression or decrease in size. Progressive Disease (PD): ≥ 25% increase in the size of the measurable lesions, or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

    Time frame: 6 months (first 6 cycles) or 3 months (first 3 cycles) for participants in the DIPG group

Secondary outcomes

  1. Percentage of Participants Who Achieved an Objective Response (ORR)

    Objective response rate was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) within the first 6 cycles of treatment (or within 3 cycles for participants in the DIPG group). Disease assessments were based on MRI and assessed by an independent central review. CR: Disappearance of all lesions and no new lesions. PR: A reduction of ≥ 50% in the size of measurable lesions compared to baseline, and/or the persistence of non-target lesions with no progression or decrease in size. Progressive Disease (PD): ≥ 25% increase in the size of the measurable lesions, or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

    Time frame: 6 months (first 6 cycles) or 3 months (first 3 cycles) for participants in the DIPG group

  2. Percentage of Participants With Long-term Stable Disease

    Long-term stable disease (SD) rate was defined as the percentage of participants who achieved SD maintained for ≥ 6 cycles (or \> 3 cycles for DIPG), measured from the date of first dose of treatment. Disease assessments were based on MRI and assessed by an independent central review. SD: A decrease of \< 50% or an increase of \< 25% in the size of measurable lesions and no evidence of new lesions, response does not meet the criteria for CR, PR, or progressive disease, and/or the persistence of non-target lesions with no progression or decrease in size. CR: Disappearance of all lesions and no new lesions. PR: A reduction of ≥ 50% in the size of measurable lesions compared to baseline, and/or the persistence of non-target lesions with no progression or decrease in size. Progressive Disease (PD): ≥ 25% increase in the size of the measurable lesions, or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

    Time frame: 6 months (first 6 cycles) or 3 months (first 3 cycles) for participants in the DIPG group

  3. Duration of Response (DoR)

    DoR is defined as the time from the date of the first objective response (complete response \[CR\] or partial response \[PR\]) to disease progression. Participants who did not have disease progression or had not died were censored at the time of their last disease assessment or at the time of start of new anticancer therapy, whichever occurred first. Progressive disease (PD): ≥ 25% increase in the size of the measurable lesions taking as a reference the smallest disease measurement recorded since the start of protocol therapy (nadir), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions, or if spine MRI and/or lumbar cerebrospinal fluid (CSF) cytology were previously negative and became positive. CR: Disappearance of all lesions and no new lesions. PR: A reduction of ≥ 50% in the size of measurable lesions compared to baseline, and/or the persistence of non-target lesions with no progression or decrease in size.

    Time frame: From the first dose of pomalidomide to the date of the first documented tumor progression or death due to any cause, whichever occurs first (Up to 71 months)

  4. Kaplan-Meier Estimate of Progression-Free Survival (PFS)

    Progression-free survival was defined as the time from the date of first dose of pomalidomide until the date progressive disease (PD) was first observed or until the date of death due to any cause, whichever occurred first. Participants who did not have PD or had not died at the time of analysis were censored at the time of their last disease assessment or at the start of new anticancer therapy, whichever occurred first. Progressive Disease (PD): ≥ 25% increase in the size of the measurable lesions taking as a reference the smallest disease measurement recorded since the start of protocol therapy (nadir), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions, or if spine MRI and/or lumbar CSF cytology were previously negative and became positive.

    Time frame: From the first dose of pomalidomide to the date of the first documented tumor progression or death due to any cause, whichever occurs first (Up to 71 months)

  5. Kaplan-Meier Estimate of Overall Survival (OS)

    Overall survival was defined as the time from the date of the first dose to the date of death (any cause). Participants who were alive were censored at the last known time that the participant was alive.

    Time frame: From the first dose of pomalidomide to the date of death due to any cause (Up to 71 months)

  6. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Treatment-emergent adverse events were defined as any adverse events (AE) occurring from the first dose of pomalidomide until 28 days after the last dose. The severity of each AE was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 and according to the following scale: Grade 1: Mild (transient or mild discomfort; no limitation in activity or medical intervention required); Grade 2: Moderate (mild to moderate limitation in activity, assistance may be needed; minimal medical intervention required); Grade 3: Severe (marked limitation in activity, assistance and medical intervention required, hospitalization possible); Grade 4: Life-threatening (extreme limitation in activity, significant assistance or medical intervention required, hospitalization or hospice care probable); Grade 5: Death. Drug-related AEs are those suspected by the Investigator as being related to administration of study drug.

    Time frame: From the first dose of pomalidomide until 28 days after the last dose (Up to approximately 72 months)

08

Results

Posted Dec 10, 2019

Participant flow

The study consisted of 4 groups, for each of the following primary brain tumor types: diffuse intrinsic pontine glioma (DIPG), ependymoma, high-grade glioma, and medulloblastoma.

Participant flow — Overall Study
MilestoneDiffuse Intrinsic Pontine GliomaEpendymomaHigh-grade GliomaMedulloblastoma
Started1192310
Received study drug1192210
Completed0010
Not completed1192210
Withdrew: Death1011
Withdrew: Progressive disease109178
Withdrew: Withdrawal by parent/guardian0021
Withdrew: Adverse event0020

Outcome measures

PrimaryPercentage of Participants With an Objective Response and Long-term Stable Disease

The percentage of participants who achieved either an objective response, defined as a complete response (CR) or partial response (PR) in the first 6 cycles of treatment (or within 3 cycles for DIPG), or long-term stable disease (SD) defined as SD maintained for ≥ 6 cycles (≥ 3 cycles for DIPG), measured from first dose date. CR: Disappearance of all lesions and no new lesions. PR: A reduction of ≥ 50% in the size of measurable lesions, and/or persistence of non-target lesions with no progression or decrease in size. SD: A decrease of \< 50% or an increase of \< 25% in the size of measurable lesions and no evidence of new lesions, response does not meet the criteria for CR, PR, or progressive disease, and/or the persistence of non-target lesions with no progression or decrease in size. Progressive Disease (PD): ≥ 25% increase in the size of the measurable lesions, or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

Time frame:
6 months (first 6 cycles) or 3 months (first 3 cycles) for participants in the DIPG group
Reported as:
Number · percentage of participants
Percentage of Participants With an Objective Response and Long-term Stable Disease
percentage of participantsDiffuse Intrinsic Pontine GliomaEpendymomaHigh-grade GliomaMedulloblastoma
Percentage of Participants With an Objective Response and Long-term Stable Disease0 (0.0 to 33.6)11.1 (0.3 to 48.2)10.5 (1.3 to 33.1)0 (0.0 to 33.6)
SecondaryPercentage of Participants Who Achieved an Objective Response (ORR)

Objective response rate was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) within the first 6 cycles of treatment (or within 3 cycles for participants in the DIPG group). Disease assessments were based on MRI and assessed by an independent central review. CR: Disappearance of all lesions and no new lesions. PR: A reduction of ≥ 50% in the size of measurable lesions compared to baseline, and/or the persistence of non-target lesions with no progression or decrease in size. Progressive Disease (PD): ≥ 25% increase in the size of the measurable lesions, or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

Time frame:
6 months (first 6 cycles) or 3 months (first 3 cycles) for participants in the DIPG group
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an Objective Response (ORR)
percentage of participantsDiffuse Intrinsic Pontine GliomaEpendymomaHigh-grade GliomaMedulloblastoma
Percentage of Participants Who Achieved an Objective Response (ORR)0 (0.0 to 33.6)0 (0.0 to 33.6)5.3 (0.1 to 26.0)0 (0.0 to 33.6)
SecondaryPercentage of Participants With Long-term Stable Disease

Long-term stable disease (SD) rate was defined as the percentage of participants who achieved SD maintained for ≥ 6 cycles (or \> 3 cycles for DIPG), measured from the date of first dose of treatment. Disease assessments were based on MRI and assessed by an independent central review. SD: A decrease of \< 50% or an increase of \< 25% in the size of measurable lesions and no evidence of new lesions, response does not meet the criteria for CR, PR, or progressive disease, and/or the persistence of non-target lesions with no progression or decrease in size. CR: Disappearance of all lesions and no new lesions. PR: A reduction of ≥ 50% in the size of measurable lesions compared to baseline, and/or the persistence of non-target lesions with no progression or decrease in size. Progressive Disease (PD): ≥ 25% increase in the size of the measurable lesions, or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

Time frame:
6 months (first 6 cycles) or 3 months (first 3 cycles) for participants in the DIPG group
Reported as:
Number · percentage of participants
Percentage of Participants With Long-term Stable Disease
percentage of participantsDiffuse Intrinsic Pontine GliomaEpendymomaHigh-grade GliomaMedulloblastoma
Percentage of Participants With Long-term Stable Disease0 (0.0 to 33.6)11.1 (0.3 to 48.2)5.3 (0.1 to 26.0)0 (0.0 to 33.6)
SecondaryDuration of Response (DoR)

DoR is defined as the time from the date of the first objective response (complete response \[CR\] or partial response \[PR\]) to disease progression. Participants who did not have disease progression or had not died were censored at the time of their last disease assessment or at the time of start of new anticancer therapy, whichever occurred first. Progressive disease (PD): ≥ 25% increase in the size of the measurable lesions taking as a reference the smallest disease measurement recorded since the start of protocol therapy (nadir), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions, or if spine MRI and/or lumbar cerebrospinal fluid (CSF) cytology were previously negative and became positive. CR: Disappearance of all lesions and no new lesions. PR: A reduction of ≥ 50% in the size of measurable lesions compared to baseline, and/or the persistence of non-target lesions with no progression or decrease in size.

Time frame:
From the first dose of pomalidomide to the date of the first documented tumor progression or death due to any cause, whichever occurs first (Up to 71 months)
Reported as:
Median · weeks
Duration of Response (DoR)
weeksDiffuse Intrinsic Pontine GliomaEpendymomaHigh-grade GliomaMedulloblastoma
Duration of Response (DoR)12.29 (NA to NA)—NA (NA to NA)—
SecondaryKaplan-Meier Estimate of Progression-Free Survival (PFS)

Progression-free survival was defined as the time from the date of first dose of pomalidomide until the date progressive disease (PD) was first observed or until the date of death due to any cause, whichever occurred first. Participants who did not have PD or had not died at the time of analysis were censored at the time of their last disease assessment or at the start of new anticancer therapy, whichever occurred first. Progressive Disease (PD): ≥ 25% increase in the size of the measurable lesions taking as a reference the smallest disease measurement recorded since the start of protocol therapy (nadir), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions, or if spine MRI and/or lumbar CSF cytology were previously negative and became positive.

Time frame:
From the first dose of pomalidomide to the date of the first documented tumor progression or death due to any cause, whichever occurs first (Up to 71 months)
Reported as:
Median · weeks
Kaplan-Meier Estimate of Progression-Free Survival (PFS)
weeksDiffuse Intrinsic Pontine GliomaEpendymomaHigh-grade GliomaMedulloblastoma
Kaplan-Meier Estimate of Progression-Free Survival (PFS)11.43 (4.43 to 12.57)8.43 (5.57 to 16.14)7.86 (5.43 to 8.29)8.29 (7.29 to 18.00)
SecondaryKaplan-Meier Estimate of Overall Survival (OS)

Overall survival was defined as the time from the date of the first dose to the date of death (any cause). Participants who were alive were censored at the last known time that the participant was alive.

Time frame:
From the first dose of pomalidomide to the date of death due to any cause (Up to 71 months)
Reported as:
Median · months
Kaplan-Meier Estimate of Overall Survival (OS)
monthsDiffuse Intrinsic Pontine GliomaEpendymomaHigh-grade GliomaMedulloblastoma
Kaplan-Meier Estimate of Overall Survival (OS)4.86 (1.02 to 10.91)12.02 (2.86 to 20.90)5.06 (2.04 to 16.66)11.60 (1.74 to 35.32)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

Treatment-emergent adverse events were defined as any adverse events (AE) occurring from the first dose of pomalidomide until 28 days after the last dose. The severity of each AE was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 and according to the following scale: Grade 1: Mild (transient or mild discomfort; no limitation in activity or medical intervention required); Grade 2: Moderate (mild to moderate limitation in activity, assistance may be needed; minimal medical intervention required); Grade 3: Severe (marked limitation in activity, assistance and medical intervention required, hospitalization possible); Grade 4: Life-threatening (extreme limitation in activity, significant assistance or medical intervention required, hospitalization or hospice care probable); Grade 5: Death. Drug-related AEs are those suspected by the Investigator as being related to administration of study drug.

Time frame:
From the first dose of pomalidomide until 28 days after the last dose (Up to approximately 72 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsDiffuse Intrinsic Pontine GliomaEpendymomaHigh-grade GliomaMedulloblastoma
Any treatment-emergent adverse event (TEAE)118219
TEAE related to study drug57148
Serious TEAE94144
Serious TEAE related to study drug1060
Grade 3/4 TEAE86146
Grade 3/4 TEAE related to study drug32104
TEAE leading to death5131
TEAE leading to dose reduction1030
TEAE leading to dose interruption4352
TEAE leading to study drug discontinuation2120

Adverse events

Collected over Participants were assessed for all-cause mortality from their first dose until their study completion (up to approximately 72 months). SAEs and other AEs were assessed from first dose until 28 days after last dose (up to approximately 72 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Diffuse Intrinsic Pontine Glioma11/11 (100%)9/11 (81.8%)11/11 (100%)
Ependymoma6/9 (66.7%)4/9 (44.4%)8/9 (88.9%)
High-grade Glioma15/23 (65.2%)14/22 (63.6%)20/22 (90.9%)
Medulloblastoma9/10 (90%)4/10 (40%)9/10 (90%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventDiffuse Intrinsic Pontine GliomaEpendymomaHigh-grade GliomaMedulloblastoma
HeadacheNervous system disorders1/112/91/220/10
HydrocephalusNervous system disorders0/112/92/220/10
General physical health deteriorationGeneral disorders2/111/92/221/10
HemiparesisNervous system disorders0/110/93/220/10
PainGeneral disorders0/111/90/220/10
EncephalitisInfections and infestations0/110/90/221/10
HyponatraemiaMetabolism and nutrition disorders0/110/91/221/10
MonoplegiaNervous system disorders0/110/90/221/10
SeizureNervous system disorders0/110/92/221/10
Transient ischaemic attackNervous system disorders0/110/90/221/10
Most frequent other events
Showing 10 of 118
Most frequent other events
EventDiffuse Intrinsic Pontine GliomaEpendymomaHigh-grade GliomaMedulloblastoma
NeutropeniaBlood and lymphatic system disorders3/117/99/224/10
LeukopeniaBlood and lymphatic system disorders3/116/98/223/10
LymphopeniaBlood and lymphatic system disorders1/116/96/220/10
VomitingGastrointestinal disorders2/114/95/224/10
HeadacheNervous system disorders3/114/95/223/10
ThrombocytopeniaBlood and lymphatic system disorders0/113/98/223/10
AnaemiaBlood and lymphatic system disorders1/113/97/222/10
RhinitisInfections and infestations0/113/91/220/10
PruritusSkin and subcutaneous tissue disorders2/113/91/221/10
Rash maculo-papularSkin and subcutaneous tissue disorders0/113/92/222/10

Baseline characteristics

The intent-to-treat population includes all enrolled participants, regardless of whether they received any treatment or not

Age, Continuous
Age, Continuous(years)Diffuse Intrinsic Pontine GliomaEpendymomaHigh-grade GliomaMedulloblastomaTotal
Median7.0 (4 to 12)12.0 (4 to 15)14.0 (5 to 18)10.0 (4 to 17)12.0 (4 to 18)
Age, Customized
Age, Customized(Participants)Diffuse Intrinsic Pontine GliomaEpendymomaHigh-grade GliomaMedulloblastomaTotal
≥ 1 to < 6 years12115
≥ 6 to < 12 years915621
≥ 12 years1617327
Sex: Female, Male
Sex: Female, Male(Participants)Diffuse Intrinsic Pontine GliomaEpendymomaHigh-grade GliomaMedulloblastomaTotal
Female448319
Male7515734
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Diffuse Intrinsic Pontine GliomaEpendymomaHigh-grade GliomaMedulloblastomaTotal
Hispanic or Latino406111
Not Hispanic or Latino7913837
Unknown or Not Reported00415
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Diffuse Intrinsic Pontine GliomaEpendymomaHigh-grade GliomaMedulloblastomaTotal
American Indian or Alaskan Native00000
Asian10203
Black or African American00202
Native Hawaiian or Other Pacific Islander00000
White10911838
Not Collected or Reported00527
Other00303
09

Study locations

22 sites
  • Stanford University Cancer Center
    Stanford, California 94305-5750, United States
  • University Of Florida
    Gainesville, Florida 32611, United States
  • Ann and Robert H Lurie Childrens Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Local Institution - 506
    Bethesda, Maryland 20892, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • Local Institution - 104
    Lille, Nord 59020, France
  • Local Institution - 102
    Lyon, 69008, France
  • Local Institution - 103
    Marseille Cedex 01, 13005, France
  • Local Institution - 100
    Paris, 75005, France
  • Local Institution - 106
    Toulouse, 31059, France
  • Local Institution - 105
    Vandoeuvre les Nancy, 54511, France
  • Local Institution - 101
    Villejuif CEDEX, 94805, France
  • Local Institution - 201
    Genova, 0, Italy
  • Local Institution - 200
    Milan, 20133, Italy
  • Local Institution - 202
    Roma, 00165, Italy
  • Local Institution - 302
    Barcelona, 8035, Spain
  • Local Institution - 300
    Madrid, 28009, Spain
  • Local Institution - 301
    Valencia, 46026, Spain
  • Local Institution - 400
    Leeds, LS7 4SA, United Kingdom
  • Local Institution - 403
    London, WC1N 3JH, United Kingdom
  • Local Institution - 401
    Sutton-Surrey, SM2 5PT, United Kingdom
10

References and documents

Publications

  • Fangusaro J, Cefalo MG, Garre ML, Marshall LV, Massimino M, Benettaib B, Biserna N, Poon J, Quan J, Conlin E, Lewandowski J, Simcock M, Jeste N, Hargrave DR, Doz F, Warren KE. Phase 2 Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors. Front Oncol. 2021 Jun 8;11:660892. doi: 10.3389/fonc.2021.660892. eCollection 2021. PubMed 34168987 ↗
  • Fangusaro J, Mitchell DA, Kocak M, Robinson GW, Baxter PA, Hwang EI, Huang J, Onar-Thomas A, Dunkel IJ, Fouladi M, Warren KE. Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial. Pediatr Blood Cancer. 2021 Feb;68(2):e28756. doi: 10.1002/pbc.28756. Epub 2020 Oct 7. PubMed 33025730 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Sep 2023, 71 months.

Of 44 industry-sponsored phase 2 interventional studies under Brain Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's 71 months is above that.

Counting every sponsor, half of 252 studies reached it within 61 months; a quarter within 38 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2017
First posted
Aug 22, 2017
StartActual
Sep 18, 2017
Primary completionActual
Sep 14, 2023
CompletionActual
Sep 14, 2023
Results first posted
Dec 10, 2019
Last update
Apr 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03257631
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Aug 22, 2017
Start date
Sep 18, 2017
Primary completion
Sep 14, 2023
Completion
Sep 14, 2023
Results posted
Dec 10, 2019
Last update
Apr 16, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pomalidomide

Start the discussion